KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Common Equity (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Common Equity for 6 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 9.29% year-over-year to $1.1 billion, compared with a TTM value of $1.1 billion through Dec 2025, up 9.29%, and an annual FY2025 reading of $1.1 billion, up 9.29% over the prior year.
  • Common Equity was $1.1 billion for Q4 2025 at Recursion Pharmaceuticals, up from $1.0 billion in the prior quarter.
  • Across five years, Common Equity topped out at $1.1 billion in Q4 2025 and bottomed at -$233.0 million in Q1 2021.
  • Average Common Equity over 5 years is $586.7 million, with a median of $509.1 million recorded in 2022.
  • Peak annual rise in Common Equity hit 503.11% in 2021, while the deepest fall reached 64.82% in 2021.
  • Year by year, Common Equity stood at $542.9 million in 2021, then decreased by 10.52% to $485.8 million in 2022, then fell by 4.6% to $463.4 million in 2023, then surged by 123.28% to $1.0 billion in 2024, then rose by 9.29% to $1.1 billion in 2025.
  • Business Quant data shows Common Equity for RXRX at $1.1 billion in Q4 2025, $1.0 billion in Q3 2025, and $919.1 million in Q2 2025.